Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study-Reference-Cited by-同舟云学术

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study

Published:2023-11 Issue:7 Volume:24 Page:e254-e258
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Zhao Shen,Chen Kehui,Shi Xinyi,Sun Jing,Fang Wenfeng,Huang Yan,Zhang Li^ORCID

Funder

Pfizer Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Cancer statistics, 2020;Siegel;CA: Cancer J Clin,2020

2. Current diagnosis and management of small-cell lung cancer;Wang;Mayo Clin Proc,2019

3. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer;Fried;J Clin Oncol: Off J Am Soc Clin Oncol,2004

4. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial;Faivre-Finn;Lancet Oncol,2017

5. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet (London, England),2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer;New England Journal of Medicine;2024-09-13